You just read:

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A

News provided by

Sangamo BioSciences, Inc.

Jan 05, 2017, 08:00 ET